Cargando…
Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs
Background: There is scanty guidance in the literature on the management of patients with glutamic acid decarboxylase (GAD65) antibody associated autoimmune epilepsy (GAD-epilepsy). GAD-epilepsy is a rare distinct neurological syndrome with a wide clinical spectrum. We describe six GAD-epilepsy pati...
Autores principales: | Mäkelä, Kari-Matti, Hietaharju, Aki, Brander, Antti, Peltola, Jukka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053535/ https://www.ncbi.nlm.nih.gov/pubmed/30057567 http://dx.doi.org/10.3389/fneur.2018.00579 |
Ejemplares similares
-
Hippocampus and Insula Are Targets in Epileptic Patients With Glutamic Acid Decarboxylase Antibodies
por: Falip, Mercè, et al.
Publicado: (2019) -
Neurological Disorders Associated with Glutamic Acid Decarboxylase Antibodies
por: Herard, Kimberly, et al.
Publicado: (2019) -
Case Report: Autoimmune Encephalitis Associated With Anti-glutamic Acid Decarboxylase Antibodies: A Pediatric Case Series
por: Ren, Changhong, et al.
Publicado: (2021) -
Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: Clinical spectrum and prognosis of a cohort from China
por: Bai, Lin, et al.
Publicado: (2022) -
Dysregulation of Ambient Glutamate and Glutamate Receptors in Epilepsy: An Astrocytic Perspective
por: Alcoreza, Oscar B., et al.
Publicado: (2021)